Designation of P2P Methyl Glycidic Acid as a List I Chemical
DEA finalizes designation of P2P methyl glycidic acid (BMK glycidic acid) and its esters, isomers, and salts as a List I chemical, imposing new recordkeeping, reporting, and security requirements on handlers.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmacies and chemical suppliers that handle, store, or distribute P2P methyl glycidic acid or related compounds. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective 30 days after publication (May 3, 2026). Existing handlers must comply immediately; new handlers must register before handling.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The substance is now classified as a DEA List I chemical, subject to regulatory controls including registration, recordkeeping, reporting of suspicious orders, and security standards.
Who it affects
Pharmacies and chemical suppliers that handle, store, or distribute P2P methyl glycidic acid or related compounds.
What you must do
Register with DEA as a List I chemical handler, implement compliance programs, and ensure all transactions are monitored and reported.
Deadline
Effective 30 days after publication (May 3, 2026). Existing handlers must comply immediately; new handlers must register before handling.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order